One million people with hepatitis C in the US at high priority for treatment
Many hepatitis C patients with cirrhosis or advanced fibrosis face liver failure and liver cancer
Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis
European HIV response "falling behind" as Eastern European epidemic grows
Safer injecting practices would be better promoted by focusing on pleasure and practical concerns – not the risk of infection
Sofosbuvir/ledipasvir with ribavirin cures most people with hepatitis C recurrence after liver transplantation
Sofosbuvir + simeprevir shows good results for hepatitis C in real-world use
DAAs show good cure rates and liver function improvement for transplant recipients with recurrent HCV
AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis
